Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids

American Journal of Clinical Pathology

Volumn 131, Issue 4, 2009, Pages 516-523

  Shen, Jian ^a,b   Pinkus, Geraldine S ^a   Deshpande, Vikram ^b   Cibas, Edmund S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Benign effusion; Cytology; EMA; Epithelial membrane antigen; Glucose transporter 1; GLUT 1; Malignant mesothelioma; X linked inhibitor of apoptosis; XIAP

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; GLUCOSE TRANSPORTER 1; X LINKED INHIBITOR OF APOPTOSIS; MUCIN 1; TUMOR MARKER; XIAP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY FLUID; CANCER DIAGNOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STAINING; AREA UNDER THE CURVE; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PLEURA EFFUSION; PLEURA TUMOR;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; MUCIN-1; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 65349097940     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPWFW7O1FVFLKT     Document Type: Article

References (39)

1. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183-1200.
2. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106-109.
3. DiBonito L, Falconieri G, Colautti I, et al. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol. 1993;9:25-31.
4. Teirstein AS. Diagnosing malignant pleural mesothelioma [editorial]. Chest. 1998;114:666-667.
5. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
6. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol. 2005;32:160-166.
7. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257.
8. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology. 1992;21:331-334.
9. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol. 2001;116:253-262.
10. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992;168:377-381.
11. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994;25:443-448.
12. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568.
13. Ramael M, Buysse C, van den Bossche J, et al. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992;167:1-4.
14. Segers K, Ramael M, Singh SK, et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. 1994;424:631-634.
15. Attanoos RL, Griffin A, Gibbs AR. The use of immunohisto- chemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet- derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231-238.
16. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
17. Saad RS, Cho P, Liu YL, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32:156-159.
18. Esteban JM, Yokota S, Husain S, et al. Immunocytochemical profile of benign and carcinomatous effusions: a practical approach to difficult diagnosis. Am J Clin Pathol. 1990;94:698-705.
19. Singh HK, Silverman JF, Berns L, et al. Significance of epithelial membrane antigen in the work-up of problematic serous effusions. Diagn Cytopathol. 1995;13:3-7.
20. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590.
21. Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618-1622.
22. Burstein DE, Reder I, Weiser K, et al. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol. 1998;11:392-396.
23. Mensch LS, Weller L, Simmons-Arnold L, et al. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions. Acta Cytol. 2002;46:813-818.
24. Afify A, Zhou H, Howell L, et al. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol. 2005;49:621-626.
25. Chandan VS, Faquin WC, Wilbur DC, et al. The utility of GLUT-1 immunolocalization in cell blocks: an adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck. Cancer. 2006;108:124-128.
26. Chang S, Lee S, Lee C, et al. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55:448-452.
27. Mellanen P, Minn H, Grenman R, et al. Expression of glucose transporters in head-and-neck tumors. Int J Cancer. 1994;56:622-629.
28. Nagase Y, Takata K, Moriyama N, et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 1995;153:798-801.
29. Weiner MF, Miranda RN, Bardales RH, et al. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. Diagn Cytopathol. 2004;31:294-299.
30. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-1051.
31. Chandan VS, Faquin WC, Wilbur DC, et al. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer. 2006;108:331-336.
32. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220.
33. Wu M, Sun Y, Li G, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol. 2007;128:783-787.
34. Jensen ML, Johansen P. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: a follow-up and comparative investigation. Diagn Cytopathol. 1996;15:33-36.
35. Deveraux QL, Leo E, Stennicke HR, et al. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242-5251.
36. Huang H, Joazeiro CA, Bonfoco E, et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem. 2000;275:26661- 26664.
37. Shiozaki EN, Chai J, Rigotti DJ, et al. Mechanism of XIAP- mediated inhibition of caspase-9. Mol Cell. 2003;11:519-527.
38. Vischioni B, van der Valk P, Span SW, et al. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol. 2006;37:78-86.
39. Kleinberg L, Lie AK, Florenes VA, et al. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol. 2007;38:986-994.